US Study Puts Psilocybin to Work Against Cancer Side Effects

A new United States-based clinical study is examining whether psilocybin, the psychoactive compound found in certain species of mushrooms, can meaningfully reduce the psychological and physical side effects that accompany cancer treatment. The research, reported by ABS-CBN News in early September 2026, marks the latest entry in a rapidly expanding body of evidence suggesting that carefully administered psychedelic-assisted therapy may offer relief where conventional pharmacological interventions have fallen short.

The study builds on a decade of foundational work at institutions such as Johns Hopkins University School of Medicine, where researchers led by Dr. Michael Griffiths demonstrated in landmark trials published in JAMA Psychiatry that a single supervised dose of psilocybin produced sustained reductions in anxiety and depression among patients with life-threatening cancers. Those earlier findings prompted the U.S. Food and Drug Administration to grant breakthrough therapy designation to related compounds and spurred a wave of Phase II and Phase III trials across North America and Europe.

According to the reporting, the current investigation focuses specifically on the constellation of side effects that erode quality of life during chemotherapy, radiation, and immunotherapy—namely treatment-related anxiety, depressive episodes, chronic fatigue, and sleep disruption. Participants receive a controlled dose of psilocybin in a structured clinical setting, accompanied by trained therapists before, during, and after the experience. Researchers are tracking both subjective well-being measures and objective biomarkers over a multi-month follow-up period to determine whether benefits persist beyond the acute session.

The regulatory backdrop for such work continues to shift. In the United States, psilocybin remains a Schedule I controlled substance under federal law, though states including Oregon and Colorado have enacted frameworks permitting licensed psilocybin services under strict oversight. The U.S. Department of Health and Human Services and the National Institutes of Health have funded multiple interventional trials, signaling institutional recognition of the compound's therapeutic potential even as full legal rescheduling has not yet occurred. In the Philippines, the Department of Health and the Philippine Drug Regulatory Agency maintain their own classification schedules, and no domestic clinical pathway for psilocybin-assisted therapy currently exists. Local practitioners in the massage therapy, spa, and allied wellness sectors therefore cannot incorporate or reference psilocybin in any client-facing protocol, and the Code on Sanitation of the Philippines along with Department of Health Committee of Examiners for Massage Therapy (CEMT) standards continue to govern all licensed bodywork practice without exception.

For the broader integrative-wellness community, the study nonetheless carries practical implications. Oncology support teams increasingly refer patients to complementary modalities—massage therapy, guided meditation, acupuncture, and nutritional counseling—as adjuncts to standard care. As psychedelic-assisted therapy moves closer to mainstream acceptance in select jurisdictions, massage therapists and spa professionals who serve oncology populations may find themselves part of a multidisciplinary continuum of care. Industry associations have begun developing continuing-education modules on trauma-informed touch, communication boundaries, and referral pathways so that bodywork practitioners can safely complement emerging pharmacological and psychedelic interventions without overstepping scope-of-practice limits.

Experts caution that the evidence base, while promising, is still maturing. Adverse events, contraindications with certain psychiatric histories, and long-term safety data remain active areas of investigation. Peer-reviewed publication of the current trial's results will be essential before any broad clinical adoption can be justified. Until then, the study represents a significant step in validating what many patients and holistic-care providers have long advocated: that addressing the mind-body dimensions of cancer treatment is not a luxury but a clinical necessity.